Q3 2024
|
11 |
160,008 |
Bicara Therapeutics Inc., NUVB, REPL, LXEO
|
13F-HR
|
11/14/2024 |
000095012324011486 |
Q2 2024
|
11 |
134,971 |
NUVB, LXEO, REPL, ENGN
|
13F-HR
|
8/14/2024 |
000095012324008730 |
Q1 2024
|
11 |
155,010 |
NUVB, LXEO, REPL, ENGN
|
13F-HR
|
5/14/2024 |
000095012324005045 |
Q4 2023
|
14 |
123,436 |
LXEO, REPL, NUVB, enGene Holdings Inc.
|
13F-HR
|
2/14/2024 |
000095012324002504 |
Q3 2023
|
12 |
108,875 |
REPL, NUVB, IKNA, MORF
|
13F-HR
|
11/14/2023 |
000095012323010476 |
Q2 2023
|
12 |
178,485 |
REPL, NUVB, ALPN, MORF
|
13F-HR
|
8/14/2023 |
000095012323007696 |
Q1 2023
|
14 |
153,322 |
REPL, NUVB, MORF, ALPN
|
13F-HR
|
5/15/2023 |
000095012323005263 |
Q4 2022
|
16 |
296,715 |
Imago Biosciences, REPL, NUVB, MORF
|
13F-HR
|
2/13/2023 |
000095012323002007 |
Q3 2022
|
19 |
273,064 |
REPL, Imago Biosciences, NUVB, CINC
|
13F-HR
|
11/14/2022 |
000095012322012070 |
Q2 2022
|
21 |
313,294 |
REPL, NUVB, Imago Biosciences, MORF
|
13F-HR
|
8/15/2022 |
000095012322009090 |
Q1 2022
|
22 |
488,614 |
NUVB, REPL, Imago Biosciences, MORF
|
13F-HR
|
5/13/2022 |
000095012322005699 |
Q4 2021
|
22 |
707,272 |
NUVB, REPL, Imago Biosciences, MORF
|
13F-HR
|
2/14/2022 |
000095012322002360 |
Q3 2021
|
26 |
891,379 |
NUVB, REPL, KRON, MORF
|
13F-HR
|
11/15/2021 |
000095012321015480 |
Q2 2021
|
2 |
279,245 |
NUVB, SANA
|
NEW HOLDINGS
|
11/15/2021 |
000095012321015607 |
Q2 2021
|
21 |
604,351 |
REPL, MORF, KRON, IKNA
|
13F-HR
|
8/16/2021 |
000095012321011084 |
Q1 2021
|
2 |
323,059 |
NUVB, SANA
|
NEW HOLDINGS
|
11/15/2021 |
000095012321015603 |
Q1 2021
|
22 |
734,164 |
REPL, MORF, KRON, IKNA
|
13F-HR
|
5/17/2021 |
000095012321006880 |
Q4 2020
|
19 |
666,876 |
REPL, KRON, MORF, SPRB
|
13F-HR
|
2/16/2021 |
000095012321002713 |
Q3 2020
|
16 |
369,660 |
REPL, MORF, GOSS, IMUX
|
13F-HR
|
11/16/2020 |
000095012320011928 |
Q2 2020
|
15 |
365,744 |
REPL, MORF, GOSS, ARQT
|
13F-HR
|
8/17/2020 |
000095012320009147 |
Q1 2020
|
16 |
241,630 |
REPL, MORF, GOSS, ARQT
|
13F-HR
|
5/14/2020 |
000095012320004802 |
Q4 2019
|
14 |
314,167 |
GOSS, REPL, MORF, TBIO
|
13F-HR
|
2/13/2020 |
000095012320001796 |
Q3 2019
|
14 |
324,015 |
GOSS, REPL, MORF, TBIO
|
13F-HR
|
11/13/2019 |
000095012319010754 |
Q2 2019
|
15 |
392,079 |
GOSS, REPL, MORF, TBIO
|
13F-HR
|
8/13/2019 |
000095012319007724 |
Q1 2019
|
13 |
311,888 |
GOSS, REPL, TBIO, PRTK
|
NEW HOLDINGS
|
5/20/2019 |
000095012319005615 |
Q1 2019
|
12 |
161,207 |
REPL, TBIO, PRTK, OBSV
|
13F-HR
|
5/15/2019 |
000095012319005079 |
Q4 2018
|
14 |
134,874 |
REPL, TBIO, KZR, PRTK
|
13F-HR
|
2/11/2019 |
000095012319001091 |
Q3 2018
|
14 |
211,385 |
REPL, PRTK, TBIO, OBSV
|
13F-HR
|
11/7/2018 |
000095012318010593 |
Q2 2018
|
13 |
135,522 |
TBIO, PRTK, OBSV, KZR
|
13F-HR
|
8/2/2018 |
000095012318007267 |
Q1 2018
|
12 |
101,754 |
PRTK, SNNA, OBSV, JNCE
|
13F-HR
|
5/4/2018 |
000095012318004151 |
Q4 2017
|
12 |
138,312 |
PRTK, JUNO, SNNA, OBSV
|
13F-HR
|
2/5/2018 |
000095012318000798 |
Q3 2017
|
11 |
176,759 |
PRTK, JUNO, FGEN, SNNA
|
13F-HR
|
11/3/2017 |
000095012317009490 |
Q2 2017
|
11 |
160,239 |
PRTK, JUNO, FGEN, NBRV
|
13F-HR
|
7/26/2017 |
000095012317006325 |
Q1 2017
|
11 |
153,841 |
PRTK, JUNO, FGEN, EGLTQ
|
13F-HR
|
5/9/2017 |
000095012317004097 |
Q4 2016
|
12 |
123,236 |
PRTK, JUNO, EGLTQ, FGEN
|
13F-HR
|
2/10/2017 |
000095012317001390 |
Q3 2016
|
11 |
130,994 |
JUNO, PRTK, EGLTQ, FGEN
|
13F-HR
|
11/2/2016 |
000095012316021058 |
Q2 2016
|
11 |
134,798 |
JUNO, PRTK, EGLTQ, FGEN
|
13F-HR
|
8/3/2016 |
000095012316018706 |
Q1 2016
|
11 |
144,173 |
JUNO, PRTK, EGLTQ, FGEN
|
13F-HR
|
5/2/2016 |
000095012316016121 |
Q4 2015
|
10 |
179,685 |
JUNO, PRTK, EGLTQ, FGEN
|
13F-HR
|
2/10/2016 |
000095012316013919 |
Q3 2015
|
10 |
177,613 |
JUNO, PRTK, EGLTQ, FGEN
|
13F-HR
|
11/4/2015 |
000095012315010742 |
Q2 2015
|
7 |
198,055 |
JUNO, PRTK, EGLTQ, FGEN
|
13F-HR
|
8/10/2015 |
000095012315008290 |
Q1 2015
|
7 |
231,250 |
JUNO, PRTK, EGLTQ, FGEN
|
13F-HR
|
5/11/2015 |
000095012315005268 |
Q4 2014
|
7 |
217,389 |
PRTK, JUNO, FGEN, EGLTQ
|
13F-HR
|
3/23/2015 |
000095012315004059 |